Genentech/OSI Raise Tarceva Price 15% In Wake Of Iressa Failure
This article was originally published in The Pink Sheet Daily
You may also be interested in...
Oncology Sales Drive Strong Quarter For Genentech
Avastin and Herceptin were each up more than 70% over the prior year’s quarter.
Oncology Sales Drive Strong Quarter For Genentech
Avastin and Herceptin were each up more than 70% over the prior year’s quarter.
Iressa Survival Data Adequately Disseminated To Physicians/Patients, Cmte. Says
AstraZeneca communication to physicians/patients on Iressa survival data has been adequate, FDA Oncologic Drugs Advisory Committee says. FDA asks committee to discuss possibility of recommending Genentech/OSI Pharma’s Tarceva as alternative to Iressa in labeling, but committee resists.